Cargando…
Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of autoimmune origin, in which inflammation and demyelination lead to neurodegeneration and progressive disability. Treatment is aimed at slowing down the course of the disease and mitigating its symptoms. One of the first-lin...
Autores principales: | Zarzuelo-Romero, María José, Pérez-Ramírez, Cristina, Cura, Yasmín, Carrasco-Campos, María Isabel, Marangoni-Iglecias, Luciana María, Ramírez-Tortosa, María Carmen, Jiménez-Morales, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540092/ https://www.ncbi.nlm.nih.gov/pubmed/34683173 http://dx.doi.org/10.3390/jpm11101032 |
Ejemplares similares
-
Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis
por: Zarzuelo Romero, María José, et al.
Publicado: (2021) -
Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007) -
The role of glatiramer acetate in the early treatment of multiple sclerosis
por: Brandes, David W
Publicado: (2010) -
Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015) -
Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018)